Le Lézard
Classified in: Business, Covid-19 virus
Subjects: SVY, ESG

Shorenstein Publishes 2022 ESG Report and Highlights Industry-Leading Achievements


SAN FRANCISCO, Aug. 9, 2022 /PRNewswire/ -- Shorenstein Properties, LLC ("Shorenstein"), an owner and operator of high-quality office, residential, and mixed-use properties across the U.S., today announced the release of its 2022 Environmental, Social and Governance (ESG) Report.

"At Shorenstein, ESG and sustainability are core to our daily operations and impact everything that we do ? both as a firm and across our portfolio. Whether it's diligence, investment execution, construction, development or day-to-day asset management, we view ESG as an opportunity to continuously improve our business while reducing our environmental impact, strengthening our communities, and empowering our teams. With our long-term approach, we measure our impact and ambitious objectives in decades, and we look forward to building on all of the successes and ongoing momentum outlined in this year's report," said Brandon Shorenstein, Chairman and CEO of Shorenstein.

Notable Highlights of Shorenstein's 2022 ESG Report include:

 

 

 

The report also details Shorenstein's increased investment in a wide range of ESG initiatives in 2021, including:

Notable Portfolio-Level Achievements

The firm also highlighted numerous ESG achievements within its nationwide portfolio. The report features select properties where Shorenstein's long-term, integrated ESG and sustainability-focused dedication has had a measurable impact on the buildings and surrounding communities, including:

To read the full report and see how Shorenstein continues to improve ESG performance, visit the Company's sustainability page: https://shorenstein.com/sustainability/

About Shorenstein Properties LLC
Founded in 1960, Shorenstein Properties LLC is a privately-owned, real estate firm that owns and operates high-quality office, residential and mixed-use properties across the U.S., with offices in San Francisco and New York. Since 1992, Shorenstein has sponsored twelve closed-end investment funds with total equity commitments of $8.8 billion, of which Shorenstein committed $723.5 million. The firm uses its integrated investment and operating capabilities to take advantage of opportunities that, at the particular time in the investment cycle, offer the most attractive returns. Investments have included ground-up developments, asset repositioning and stabilized assets; investment structures have included asset acquisitions, mezzanine loans, preferred equity investments and structured joint ventures. More information is available at www.shorenstein.com.

Contact
Jon Keehner / Woomi Yun / Erik Carlson
Joele Frank, Wilkinson Brimmer Katcher
212.355.4449

SOURCE Shorenstein Properties LLC


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: